2000 issue 3


Volume 16, issue 3


Farmakologiczne leczenie spastyczności w przebiegu stwardnienia rozsianego

Wojciech Wicha1
1. II Klinika Neurologiczna Instytutu Psychiatrii i Neurologii w Warszawie
Farmakoterapia w Psychiatrii i Neurologii, 2000, 3, 275-283


Multiple sclerosis is common neurological entity and spasticity is widespread and debilitating condition affecting quality of life of MS patients. While not all cases of spasticity need to be, or even should be, treated, the physician now has available a wide range of potentially effective treatments. Strengths and weaknesses of each option play an important role in treatment decision-making.